Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821055 | 0.96 | KIT (1.00) | KITBRAF | |
| SCHEMBL5819463 | 0.86 | KIT (0.83) | KITBRAF | |
| SCHEMBL5790091 | 0.86 | KIT (0.83) | KITBRAF | |
| SCHEMBL4312992 | 0.86 | KIT (1.00) | KITBRAF | |
| SCHEMBL5808481 | 0.86 | KIT (0.82) | KITBRAF | |
| SCHEMBL5808899 | 0.86 | KIT (0.81) | KITBRAF | |
| SCHEMBL5807439 | 0.84 | KIT (0.80) | KITBRAF | |
| SCHEMBL4623464 | 0.84 | KIT (0.90) | KITBRAF | |
| SCHEMBL5819532 | 0.84 | KIT (0.79) | KITBRAF | |
| SCHEMBL4946927 | 0.84 | KIT (0.72) | KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590328-B1 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2012-02-22 | — | — | EP | claimed |
| JP-4685755-B2 | — | — | 2011-05-18 | — | — | JP | claimed |
| WO-2010088000-A2 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2010-08-05 | — | — | WO | claimed |
| EP-1590328-A4 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1590328-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| US-6949563-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2005-09-27 | — | — | US | claimed |
| US-20040186124-A1 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004063330-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-1590328-B1 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010088000-A2 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-7696225-B2 | (2-carboxamido)(3-Amino) thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7524859-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1590328-A4 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060247275-A1 | (2-carboxamido)(3-amino)thiophene compounds | CREW ANDREW P | 2006-11-02 | — | — | US | disclosed |
| EP-1590328-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6949563-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2005-09-27 | — | — | US | disclosed |
| US-20050192320-A1 | (2-Carboxamido)(3-amino)thiophene compounds | CREW ANDREW P (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050154014-A1 | (2-carboxamido)(3-amino) thiophene compounds | OSI PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20040186124-A1 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004063330-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186124-A1 | (2-carboxamido)(3-amino)thiophene compounds | ABL1, NAT1, KRAS | KIT 1833/4885BRAF 195/4885 |
| US-20050154014-A1 | (2-carboxamido)(3-amino) thiophene compounds | AADAC, PAM, TPMT | KIT 4457/4885BRAF 678/4885 |
| US-20060247275-A1 | (2-carboxamido)(3-amino)thiophene compounds | PCNA, MKI67, MYC | KIT 325/4885BRAF 75/4885 |
| US-20050192320-A1 | (2-Carboxamido)(3-amino)thiophene compounds | PCNA, MKI67, TPMT | KIT 289/4885BRAF 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.